Pharmaceutical leader GSK has announced a $30 billion investment plan over five years targeting manufacturing and research and development infrastructure across the United States. This infusion includes new biologics facilities and technology upgrades in several states. The initiative aligns with broader industry trends emphasizing reshoring of drug production and expanded clinical trial operations amid geopolitical and regulatory pressures. GSK’s CEO emphasized the strategic value of the US market and bolstered transatlantic scientific cooperation.